Role of the histone H3 lysine 9 methyltransferase Suv39 h1 in maintaining Epsteinn-Barr virus latency in B95-8 cells

FEBS Journal

Volumn 281, Issue 9, 2014, Pages 2148-2158

  Imai, Kenichi ^a   Kamio, Noriaki ^a   Cueno, Marni E ^a   Saito, Yuko ^a   Inoue, Hiroko ^b   Saito, Ichiro ^b   Ochiai, Kuniyasu ^a  

^a NIHON UNIVERSITY   (Japan)

^b TSURUMI UNIVERSITY   (Japan)

Author keywords

BZLF1; EBV; histone methylation; latency; Suv39 h1

Indexed keywords

CHETOCIN; HISTONE H4; HISTONE LYSINE METHYLTRANSFERASE; IMMEDIATE EARLY PROTEIN BZLF1; PROTEIN INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BZLF1 GENE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HISTONE METHYLATION; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; PROMOTER REGION; TRIMETHYLATION; VIRUS GENE; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

BZLF1; EBV; HISTONE METHYLATION; LATENCY; SUV39 H1;

CELL LINE; CHROMATIN ASSEMBLY AND DISASSEMBLY; GENE EXPRESSION REGULATION, VIRAL; GENE KNOCKDOWN TECHNIQUES; HERPESVIRUS 4, HUMAN; HISTONE DEACETYLASE INHIBITORS; HUMANS; METHYLTRANSFERASES; PIPERAZINES; REPRESSOR PROTEINS; TRANS-ACTIVATORS; VIRUS LATENCY;

EID: 84899949147     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12768     Document Type: Article

References (58)

1. Berger SL, (2007) The complex language of chromatin regulation during transcription. Nature 447, 407-412.
2. Li B, Carey M, &, Workman JL, (2007) The role of chromatin during transcription. Cell 128, 707-719.
3. Hakre S, Chavez L, Shirakawa K, &, Verdin E, (2012) HIV latency: experimental systems and molecular models. FEMS Microbiol Rev 36, 706-716.
4. Guise AJ, Budayeva HG, Diner BA, &, Cristea IM, (2013) Histone deacetylases in herpesvirus replication and virus-stimulated host defense. Viruses 5, 1607-1632.
5. Takacs M, Banati F, Koroknai A, Segesdi J, Salamon D, Wolf H, Niller HH, &, Minarovits J, (2010) Epigenetic regulation of latent Epstein-Barr virus promoters. Biochim Biophys Acta 1799, 228-235.
6. Chen MR, (2011) Epstein-Barr virus, the immune system, and associated diseases. Front Microbiol 2, 5.
7. Thompson MP, &, Kurzrock R, (2004) Epstein-Barr virus and cancer. Clin Cancer Res 10, 803-821.
8. Speck SH, Chatila T, &, Flemington E, (1997) Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene. Trends Microbiol 5, 399-405.
9. Countryman JK, Gradoville L, &, Miller G, (2008) Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors. J Virol 82, 4706-4719.
10. Bryant H, &, Farrell PJ, (2002) Signal transduction and transcription factor modification during reactivation of Epstein-Barr virus from latency. J Virol 76, 10290-10298.
11. Murata T, Noda C, Saito S, Kawashima D, Sugimoto A, Isomura H, Kanda T, Yokoyama KK, &, Tsurumi T, (2011) Involvement of Jun dimerization protein 2 (JDP2) in the maintenance of Epstein-Barr virus latency. J Biol Chem 286, 22007-22016.
12. Gruffat H, Manet E, &, Sergeant A, (2002) MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling. EMBO Rep 3, 141-146.
13. Daigle D, Gradoville L, Tuck D, Schulz V, Wang'ondu R, Ye J, Gorres K, &, Miller G, (2011) Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-Barr virus lytic cycle. J Virol 85, 5628-5643.
14. Luka J, Kallin B, &, Klein G, (1979) Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94, 228-231.
15. Saemundsen AK, Kallin B, &, Klein G, (1980) Effect of n-butyrate on cellular and viral DNA synthesis in cells latently infected with Epstein-Barr virus. Virology 107, 557-561.
16. Imai K, Inoue H, Tamura M, Cueno ME, Inoue H, Takeichi O, Kusama K, Saito I, &, Ochiai K, (2012) The periodontal pathogen Porphyromonas gingivalis induces the Epstein-Barr virus lytic switch transactivator ZEBRA by histone modification. Biochimie 94, 839-846.
17. Jenuwein T, (2006) The epigenetic magic of histone lysine methylation. FEBS J 273, 3121-3135.
18. Mosammaparast N, &, Shi Y, (2010) Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu Rev Biochem 79, 155-179.
19. Lee DY, Teyssier C, Strahl BD, &, Stallcup MR, (2005) Role of protein methylation in regulation of transcription. Endocr Rev 26, 147-170.
20. Baylin SB, &, Ohm JE, (2006) Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6, 107-116.
21. Yoo CB, &, Jones PA, (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5, 37-50.
22. Melcher M, Schmid M, Aagaard L, Selenko P, Laible G, &, Jenuwein T, (2000) Structure-function analysis of SUV39H1 reveals a dominant role in heterochromatin organization, chromosome segregation, and mitotic progression. Mol Cell Biol 20, 3728-3741.
23. Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, Opravil S, Mechtler K, Ponting CP, Allis CD, et al,. (2000) Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406, 593-599.
24. Lieberman PM, (2008) Chromatin organization and virus gene expression. J Cell Physiol 216, 295-302.
25. du Chéné I, Basyuk E, Lin YL, Triboulet R, Knezevich A, Chable-Bessia C, Mettling C, Baillat V, Reynes J, Corbeau P, et al,. (2007) Suv39H1 and HP1γ are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J 26, 424-435.
26. Imai K, Togami H, &, Okamoto T, (2010) Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem 285, 16538-16545.
27. Murata T, Kondo Y, Sugimoto A, Kawashima D, Saito S, Isomura H, Kanda T, &, Tsurumi T, (2012) Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells. J Virol 86, 4752-4761.
28. Kraus RJ, Mirocha SJ, Stephany HM, Puchalski JR, &, Mertz JE, (2001) Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus. J Virol 75, 867-877.
29. Greiner D, Bonaldi T, Eskeland R, Roemer E, &, Imhof A, (2005) Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol 1, 143-145.
30. Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML, Rea S, Mechtler K, Kowalski JA, Homon CA, et al,. (2007) Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 25, 473-481.
31. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, &, Yu Q, (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21, 1050-1063.
32. Cameron EE, Bachman KE, Myohanen S, Herman JG, &, Baylin SB, (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21, 103-107.
33. Countryman J, Gradoville L, Bhaduri-McIntosh S, Ye J, Heston L, Himmelfarb S, Shedd D, &, Miller G, (2009) Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus. J Virol 83, 10694-10709.
34. Gradoville L, Kwa D, El-Guindy A, &, Miller G, (2002) Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle. J Virol 76, 5612-5626.
35. Liang Y, Vogel JL, Narayanan A, Peng H, &, Kristie TM, (2009) Inhibition of the histone demethylase LSD1 blocks α-herpesvirus lytic replication and reactivation from latency. Nat Med 15, 1312-1317.
36. Narayanan A, Ruyechan WT, &, Kristie TM, (2007) The coactivator host cell factor-1 mediates Set1 and MLL1 H3K4 trimethylation at herpesvirus immediate early promoters for initiation of infection. Proc Natl Acad Sci USA 104, 10835-10840.
37. Wysocka J, Myers MP, Laherty CD, Eisenman RN, &, Herr W, (2003) Human Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3-K4 methyltransferase are tethered together selectively by the cell-proliferation factor HCF-1. Genes Dev 17, 896-911.
38. Tempera I, Wiedmer A, Dheekollu J, &, Lieberman PM, (2010) CTCF prevents the epigenetic drift of EBV latency promoter Qp. PLoS Pathog 6, e1001048.
39. Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, Fukuda M, Takeda N, Niida H, Kato H, et al,. (2002) G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev 16, 1779-1791.
40. Rice JC, Briggs SD, Ueberheide B, Barber CM, Shabanowitz J, Hunt DF, Shinkai Y, &, Allis CD, (2003) Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol Cell 12, 1591-1598.
41. Spensberger D, &, Delwel R, (2008) A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a. FEBS Lett 582, 2761-2767.
42. Cattaneo F, &, Nucifora G, (2008) EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression. J Cell Biochem 105, 344-352.
43. Jang H, Choi DE, Kim H, Cho EJ, &, Youn HD, (2007) Cabin1 represses MEF2 transcriptional activity by association with a methyltransferase, SUV39H1. J Biol Chem 282, 11172-11179.
44. Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, Allshire RC, &, Kouzarides T, (2001) Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410, 120-124.
45. Schotta G, Ebert A, Krauss V, Fischer A, Hoffmann J, Rea S, Jenuwein T, Dorn R, &, Reuter G, (2002) Central role of Drosophila SU(VAR)3-9 in histone H3-K9 methylation and heterochromatic gene silencing. EMBO J 21, 1121-1131.
46. Zhang CL, McKinsey TA, &, Olson EN, (2002) Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol Cell Biol 22, 7302-7312.
47. Yamamoto K, &, Sonoda M, (2003) Self-interaction of heterochromatin protein 1 is required for direct binding to histone methyltransferase, SUV39H1. Biochem Biophys Res Commun 301, 287-292.
48. Fischer T, Cui B, Dhakshnamoorthy J, Zhou M, Rubin C, Zofall M, Veenstra TD, &, Grewal SI, (2009) Diverse roles of HP1 proteins in heterochromatin assembly and functions in fission yeast. Proc Natl Acad Sci USA 106, 8998-9003.
49. Kelly TK, De Carvalho DD, &, Jones PA, (2010) Epigenetic modifications as therapeutic targets. Nat Biotechnol 28, 1069-1078.
50. Chi P, Allis CD, &, Wang GG, (2010) Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 10, 457-469.
51. Jayaraman S, (2011) Epigenetics of autoimmune diabetes. Epigenomics 3, 639-648.
52. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, et al,. (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109, 31-39.
53. Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, Bastianelli E, Baron R, Rawadi G, &, Clement-Lacroix P, (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 150, 862-872.
54. Copeland RA, Solomon ME, &, Richon VM, (2009) Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 8, 724-732.
55. Rotili D, &, Mai A, (2011) Targeting histone demethylases: a new avenue for the fight against cancer. Genes Cancer 2, 663-679.
56. Sanda T, Okamoto T, Uchida Y, Nakagawa H, Iida S, Kayukawa S, Suzuki T, Oshizawa T, Suzuki T, Miyata N, et al,. (2007) Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia 21, 2344-2353.
57. Inoue H, Mishima K, Yamamoto-Yoshida S, Ushikoshi-Nakayama R, Nakagawa Y, Yamamoto K, Ryo K, Ide F, &, Saito I, (2012) Aryl hydrocarbon receptor-mediated induction of EBV reactivation as a risk factor for Sjogren's syndrome. J Immunol 188, 4654-4662.
58. Imai K, Ochiai K, &, Okamoto T, (2009) Reactivation of latent HIV-1 infection by the periodontopathic bacterium Porphyromonas gingivalis involves histone modification. J Immunol 182, 3688-3695.